Company profile
REVOLUTION MEDICINES, INC.
NASDAQ:RVMDBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RASONQUE | approved | $0.0MQ4 2024 | 14 | approved |
| ZOLDONRASIB | phase3 | — | 8 | active |
| VOCIPROTAFIB | phase2 | — | 4 | active |
| ELIRONRASIB | phase1_2 | — | 4 | active |
| RMC-5552 | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05054725 | phase2 | completed | 2021-12-30 | 2024-07-03 | Revolution Medicines, Inc. | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies |
| NCT05462717 | phase1 | active_not_recruiting | 2022-09-19 | 2027-03-31 | Revolution Medicines, Inc. | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors |
| NCT03634982 | phase1 | unknown | 2018-09-28 | 2023-03-31 | Revolution Medicines, Inc. | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors |
| NCT04774952 | phase1 | completed | 2021-04-07 | 2024-05-06 | Revolution Medicines, Inc. | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors |
| NCT03989115 | phase1_2 | completed | 2019-07-02 | 2022-02-08 | Revolution Medicines, Inc. | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 220910 | 2026-08-26 | NDA | REVOLUTION MEDICINES | |||||
Loading… | ||||||||